InnoCare Pharma has dosed the first patient in a global Phase II clinical trial for Soficitinib, a TYK2 inhibitor for prurigo nodularis treatment in China. Soficitinib targets T-cell related autoimmune disorders and dermatological conditions, such as atopic dermatitis and vitiligo. Prurigo nodularis affects about 10 million patients worldwide and the market is expected to grow to $3 billion by 2034. InnoCare’s CEO, Dr. Jasmine Cui, highlighted the potential of Soficitinib for autoimmune diseases. The company focuses on developing innovative therapies for cancers and autoimmune diseases with unmet medical needs globally.

Read more at GlobeNewswire: InnoCare Announces First Patient Dosed in the Global Phase